Danish pharmaceutical company Novo Nordisk on Wednesday reported an increase in sales of 31% in Danish kroner and 36% at constant exchange rates (CER) to $33.71 billion in 2023. Full-year operating profit jumped by 37% in kroner and 44% at constant exchange rates to 102.6 billion.

